Theriva Biologics, Inc.
TOVX
$0.4996
-$0.0304-5.74%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.39M | 6.70M | 6.87M | 6.97M | 7.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.94M | 18.73M | 20.21M | 21.58M | 22.27M |
| Operating Income | -17.94M | -18.73M | -20.21M | -21.58M | -22.27M |
| Income Before Tax | -24.81M | -25.65M | -27.12M | -23.22M | -20.35M |
| Income Tax Expenses | -- | -- | -424.00K | -951.00K | -1.31M |
| Earnings from Continuing Operations | -24.81 | -25.65 | -26.69 | -22.27 | -19.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.81M | -25.65M | -26.69M | -22.27M | -19.04M |
| EBIT | -17.94M | -18.73M | -20.21M | -21.58M | -22.27M |
| EBITDA | -17.81M | -18.59M | -20.06M | -21.43M | -22.13M |
| EPS Basic | -20.68 | -26.65 | -33.09 | -31.13 | -28.79 |
| Normalized Basic EPS | -7.93 | -11.48 | -15.63 | -18.24 | -19.76 |
| EPS Diluted | -20.68 | -26.65 | -33.09 | -31.13 | -28.79 |
| Normalized Diluted EPS | -7.93 | -11.48 | -15.63 | -18.24 | -19.76 |
| Average Basic Shares Outstanding | 7.49M | 5.39M | 3.28M | 2.83M | 2.66M |
| Average Diluted Shares Outstanding | 7.49M | 5.39M | 3.28M | 2.83M | 2.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |